Patient characteristics
. | Hopkins . | Nebraska . | IBMTR . | FHCRC . | Minnesota . |
|---|---|---|---|---|---|
| n | 151 | 60 | 708 | 188 | 149 |
| Median age, y (range) | 33 (4-62) | 40 (17-60) | 35 (16-60) | 37 (1-70) | 29 (1-52) |
| Age groups, n (%) | |||||
| Younger than 10 y | 7 (5) | 0 (0) | 0 | 18 (10) | 25 (17) |
| 10-20 y | 16 (11) | 1 (2) | 55 (8) | 26 (14) | 24 (16) |
| 21-40 y | 86 (60) | 32 (53) | 411 (58) | 66 (35) | 68 (46) |
| Older than 40 y | 42 (28) | 27 (45) | 242 (34) | 78 (41) | 32 (21) |
| Male/female, n (%) | 89 (59)/62 (41) | 35 (58)/25 (42) | 415 (59)/293 (41) | 113 (60)/75 (40) | 88 (59)/61 (41) |
| Donor-patient sex mismatch, n (%) | |||||
| None | 76/151 (51) | 36 (60) | 358 (51) | 86 (46) | 71 (48) |
| Female to male | 44/151 (29) | 14 (23) | 213 (30) | 52 (28) | 52 (35) |
| Male to female | 30/151 (20) | 10 (17) | 137 (19) | 50 (27) | 26 (17) |
| Diagnosis, n (%) | |||||
| Aplastic anemia | 4 (3) | 0 | 0 | 2 (1) | 16 (11) |
| Acute leukemia | 59 (39) | 17 (28) | 304 (43) | 63 (34) | 40 (27) |
| CML | 69 (46) | 22 (37) | 404 (57) | 76 (40) | 59 (39) |
| Lymphoma/CLL | 13 (9) | 10 (17) | 0 | 20 (11) | 4 (3) |
| Others | 6 (4) | 11 (18) | 0 | 27 (14) | 30 (20) |
| Disease status, n (%) | |||||
| Early (CR1 and chronic phase) | 93 (62) | 26 (43) | 562 (79) | 92 (60) | 54 (36) |
| Late (all others) | 58 (38) | 34 (57) | 146 (21) | 61 (40) | 95 (64) |
| Donor type, n (%) | |||||
| HLA-identical, related | 140 (93) | 60 (100) | 708 (100) | 51 (27) | 96 (64) |
| HLA-identical, unrelated | 7 (5) | 0 | 0 | 117 (62) | 18 (12) |
| Non-HLA-matched | 4 (2) | 0 | 0 | 20 (11) | 35 (24) |
| Transplantation year, n (%) | |||||
| 1979-1989 | 80 (53) | 0 | 0 | 0 (0) | 72 (48) |
| 1990-1998 | 71 (47) | 60 (100) | 708 (100) | 188 (100) | 77 (52) |
| Conditioning regimen, n (%) | |||||
| Cy-TBI | 71 (47) | 12 (20) | 708 (100) | 139 (74) | 98 (66) |
| Bu-Cy | 62 (41) | 1 (2) | 0 | 29 (15) | 10 (7) |
| Bu-Cy-VP16 or others | 18 (12) | 47 (78) | 0 | 20 (11) | 41 (27) |
| Source of stem cells, n (%) | |||||
| Bone marrow | 151 (100) | 39 (65) | 708 (100) | 157 (84) | 149 (100) |
| Blood | 0 | 21 (35) | 0 | 31 (16) | 0 |
| GVHD prophylaxis, n (%) | |||||
| CSA±MTX | 141 (93) | 60 (100) | 708 (100) | 156 (83) | 33 (22) |
| FK506 + MTX | 0 | 0 | 7 (4) | 9 (6) | |
| Others | 10 (7) | 0 | 0 | 25 (13) | 100 (68) |
| None | 0 | 0 | 0 | 0 | 2 (1) |
| T-cell depletion, n (%) | 33 (22) | 0 | 0 | 6 (3) | 5 (3) |
| Positive CMV status, n (%) | 79/138 (57) | 25 (42) | 555† (78) | 70 (38) | 100 (67) |
| ABO incompatibility, n (%) | 43/143 (30) | N/A | N/A | N/A | N/A |
| Acute GVHD stage, n (%) | |||||
| 0 | 31/151 (21) | 15 (25) | 247 (35) | 4 (3) | 19 (13) |
| 1 (cutaneous) | 65/151 (43) | 12 (20) | 198 (28) | 3 (2) | 18 (12) |
| 2-4 (systemic) | 55/151 (36) | 33 (55) | 263 (37) | 136 (95) | 112 (75) |
| Follow-up,* y after diagnosis of cGVHD, median (range) | 8.3 (0.2-20.6) | 4.3 (0.5-7.5) | 1.2 (0.1-5.2) | 1.6 (0.1-5.1) | 8.4 (0.7-13.4) |
| Mode of presentation of cGVHD, n (%) | |||||
| Progressive | 53 (35) | 16 (27) | 156 (22) | 53 (28) | 69 (46) |
| Quiescent | 67 (44) | 32 (53) | 306 (43) | 115 (61) | 62 (42) |
| De novo | 31 (21) | 12 (20) | 246 (35) | 20 (11) | 18 (12) |
| Skin extent, n (%) | |||||
| None | 32 (21) | 40 (66) | 209 (30)‡ | 76 (40) | 34 (23) |
| 50% or less | 52 (34) | 5 (9) | 318 (45)‡ | 70 (37) | 7 (5) |
| More than 50% | 67 (45) | 15 (25)§ | 181 (26)‡ | 42 (22) | 108 (72)§ |
| Weight loss, n (%) | |||||
| None | 41/150 (27) | N/A | 546 (77) | N/A | N/A |
| Less than 10% from baseline (BMT) | 50/150 (33) | N/A | N/A | N/A | N/A |
| 10% or more from baseline (BMT) | 59/150 (40) | N/A | N/A | N/A | N/A |
| Karnofsky performance status, n (%) | |||||
| Greater than 80% | 84 (56) | N/A | 303 (43) | 74 (64) | N/A |
| 50%-80% | 57 (38) | N/A | 385 (54) | 36 (31) | N/A |
| Less than 50% | 10 (6) | N/A | 20 (3) | 5 (4) | N/A |
| Mouth/eye involvement, n (%) | |||||
| Asymptomatic | 31 (20) | N/A | 233 (33) | N/A | 101 (68)∥ |
| Symptomatic | 99 (66) | N/A | Either 317 (45) | N/A | 48 (32)∥ |
| Functional compromise | 21 (14) | N/A | Both 158 (22) | N/A | |
| Thrombocytopenia less than 100 000/μL, n (%) | 71 (47) | 26 (43) | 265 (37) | 129 (69) | 88 (59) |
. | Hopkins . | Nebraska . | IBMTR . | FHCRC . | Minnesota . |
|---|---|---|---|---|---|
| n | 151 | 60 | 708 | 188 | 149 |
| Median age, y (range) | 33 (4-62) | 40 (17-60) | 35 (16-60) | 37 (1-70) | 29 (1-52) |
| Age groups, n (%) | |||||
| Younger than 10 y | 7 (5) | 0 (0) | 0 | 18 (10) | 25 (17) |
| 10-20 y | 16 (11) | 1 (2) | 55 (8) | 26 (14) | 24 (16) |
| 21-40 y | 86 (60) | 32 (53) | 411 (58) | 66 (35) | 68 (46) |
| Older than 40 y | 42 (28) | 27 (45) | 242 (34) | 78 (41) | 32 (21) |
| Male/female, n (%) | 89 (59)/62 (41) | 35 (58)/25 (42) | 415 (59)/293 (41) | 113 (60)/75 (40) | 88 (59)/61 (41) |
| Donor-patient sex mismatch, n (%) | |||||
| None | 76/151 (51) | 36 (60) | 358 (51) | 86 (46) | 71 (48) |
| Female to male | 44/151 (29) | 14 (23) | 213 (30) | 52 (28) | 52 (35) |
| Male to female | 30/151 (20) | 10 (17) | 137 (19) | 50 (27) | 26 (17) |
| Diagnosis, n (%) | |||||
| Aplastic anemia | 4 (3) | 0 | 0 | 2 (1) | 16 (11) |
| Acute leukemia | 59 (39) | 17 (28) | 304 (43) | 63 (34) | 40 (27) |
| CML | 69 (46) | 22 (37) | 404 (57) | 76 (40) | 59 (39) |
| Lymphoma/CLL | 13 (9) | 10 (17) | 0 | 20 (11) | 4 (3) |
| Others | 6 (4) | 11 (18) | 0 | 27 (14) | 30 (20) |
| Disease status, n (%) | |||||
| Early (CR1 and chronic phase) | 93 (62) | 26 (43) | 562 (79) | 92 (60) | 54 (36) |
| Late (all others) | 58 (38) | 34 (57) | 146 (21) | 61 (40) | 95 (64) |
| Donor type, n (%) | |||||
| HLA-identical, related | 140 (93) | 60 (100) | 708 (100) | 51 (27) | 96 (64) |
| HLA-identical, unrelated | 7 (5) | 0 | 0 | 117 (62) | 18 (12) |
| Non-HLA-matched | 4 (2) | 0 | 0 | 20 (11) | 35 (24) |
| Transplantation year, n (%) | |||||
| 1979-1989 | 80 (53) | 0 | 0 | 0 (0) | 72 (48) |
| 1990-1998 | 71 (47) | 60 (100) | 708 (100) | 188 (100) | 77 (52) |
| Conditioning regimen, n (%) | |||||
| Cy-TBI | 71 (47) | 12 (20) | 708 (100) | 139 (74) | 98 (66) |
| Bu-Cy | 62 (41) | 1 (2) | 0 | 29 (15) | 10 (7) |
| Bu-Cy-VP16 or others | 18 (12) | 47 (78) | 0 | 20 (11) | 41 (27) |
| Source of stem cells, n (%) | |||||
| Bone marrow | 151 (100) | 39 (65) | 708 (100) | 157 (84) | 149 (100) |
| Blood | 0 | 21 (35) | 0 | 31 (16) | 0 |
| GVHD prophylaxis, n (%) | |||||
| CSA±MTX | 141 (93) | 60 (100) | 708 (100) | 156 (83) | 33 (22) |
| FK506 + MTX | 0 | 0 | 7 (4) | 9 (6) | |
| Others | 10 (7) | 0 | 0 | 25 (13) | 100 (68) |
| None | 0 | 0 | 0 | 0 | 2 (1) |
| T-cell depletion, n (%) | 33 (22) | 0 | 0 | 6 (3) | 5 (3) |
| Positive CMV status, n (%) | 79/138 (57) | 25 (42) | 555† (78) | 70 (38) | 100 (67) |
| ABO incompatibility, n (%) | 43/143 (30) | N/A | N/A | N/A | N/A |
| Acute GVHD stage, n (%) | |||||
| 0 | 31/151 (21) | 15 (25) | 247 (35) | 4 (3) | 19 (13) |
| 1 (cutaneous) | 65/151 (43) | 12 (20) | 198 (28) | 3 (2) | 18 (12) |
| 2-4 (systemic) | 55/151 (36) | 33 (55) | 263 (37) | 136 (95) | 112 (75) |
| Follow-up,* y after diagnosis of cGVHD, median (range) | 8.3 (0.2-20.6) | 4.3 (0.5-7.5) | 1.2 (0.1-5.2) | 1.6 (0.1-5.1) | 8.4 (0.7-13.4) |
| Mode of presentation of cGVHD, n (%) | |||||
| Progressive | 53 (35) | 16 (27) | 156 (22) | 53 (28) | 69 (46) |
| Quiescent | 67 (44) | 32 (53) | 306 (43) | 115 (61) | 62 (42) |
| De novo | 31 (21) | 12 (20) | 246 (35) | 20 (11) | 18 (12) |
| Skin extent, n (%) | |||||
| None | 32 (21) | 40 (66) | 209 (30)‡ | 76 (40) | 34 (23) |
| 50% or less | 52 (34) | 5 (9) | 318 (45)‡ | 70 (37) | 7 (5) |
| More than 50% | 67 (45) | 15 (25)§ | 181 (26)‡ | 42 (22) | 108 (72)§ |
| Weight loss, n (%) | |||||
| None | 41/150 (27) | N/A | 546 (77) | N/A | N/A |
| Less than 10% from baseline (BMT) | 50/150 (33) | N/A | N/A | N/A | N/A |
| 10% or more from baseline (BMT) | 59/150 (40) | N/A | N/A | N/A | N/A |
| Karnofsky performance status, n (%) | |||||
| Greater than 80% | 84 (56) | N/A | 303 (43) | 74 (64) | N/A |
| 50%-80% | 57 (38) | N/A | 385 (54) | 36 (31) | N/A |
| Less than 50% | 10 (6) | N/A | 20 (3) | 5 (4) | N/A |
| Mouth/eye involvement, n (%) | |||||
| Asymptomatic | 31 (20) | N/A | 233 (33) | N/A | 101 (68)∥ |
| Symptomatic | 99 (66) | N/A | Either 317 (45) | N/A | 48 (32)∥ |
| Functional compromise | 21 (14) | N/A | Both 158 (22) | N/A | |
| Thrombocytopenia less than 100 000/μL, n (%) | 71 (47) | 26 (43) | 265 (37) | 129 (69) | 88 (59) |
Except where otherwise indicated all data are numbers of patients, with percentages in parentheses
CML indicates chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; CR, complete remission; Cy, cytarabine; TBI, total body irradiation; Bu, busulfan; CMV, cytomegalovirus; BMT, bone marrow transplantation; N/A, not available
*Of surviving patients
†Either patient or donor CMV+ or unknown
‡Extent of skin involvement was considered greater than 50% BSA if skin GVHD was originally recorded as “moderate” or “severe” in the IBMTR data collection forms
§Extent of skin involvement was considered greater than 50% BSA if cGVHD was classified as “extensive” with skin involvement
In the Minnesota study, mouth/eye involvement was considered “present” (symptomatic) or “absent” (asymptomatic)